Loss of lysophospholipase 3 increases atherosclerosis in apolipoprotein E-deficient mice

  • Taniyama Y
  • Fuse H
  • Satomi T
 et al. 
  • 11


    Mendeley users who have this article in their library.
  • 10


    Citations of this article.


Human LCAT-like lysophospholipase (LLPL), or lysophospholipase 3, was first identified in vitro, in foam cells derived from THP-1 cells. We demonstrated that LLPL was present in foam cells in the severe atherosclerotic lesions that develop in apolipoprotein E-null (apoE-/-) mice. This indicated that LLPL might affect lipid metabolisms in foam cells and, therefore, atherogenesis. Accordingly, we created LLPL-knockout mice by gene targeting and crossed them with apoE-/-mice. We showed that the absence of LLPL increased lesion formation markedly in apoE-/-mice but had little effect on the plasma-lipid profile. In addition, LLPL-deficient peritoneal macrophages were more sensitive to apoptosis induced by exposure to oxidized low-density lipoprotein. LLPL might provide a link between apoptosis in macrophages and atherogenesis. Our data demonstrate that LLPL activity is anti-atherogenic and indicate that the regulation of this enzyme might be a novel drug target for the treatment of atherosclerosis. © 2005 Elsevier Inc. All rights reserved.

Author-supplied keywords

  • Acylceramide synthase
  • Apoptosis
  • Atherosclerosis
  • Knockout mice
  • LLPL
  • Lysophospholipase 3
  • Lysosomal phospholipase A2
  • Macrophage
  • Oxidized LDL

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Yoshio Taniyama

  • Hiromitsu Fuse

  • Tomoko Satomi

  • Ryuichi Tozawa

  • Yoshitaka Yasuhara

  • Kozo Shimakawa

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free